Tuesday newspaper round-up: Tax havens, Lagarde, AstraZeneca, Brexit
20th Dec 2016 07:20
(ShareCast News) - The UK's overseas territories face renewed pressure to abandon corporate secrecy after 80 MPs joined forces to demand greater financial transparency from offshore havens. The cross-party group is backing an amendment to the government's criminal finances bill on Tuesday that would
Read moreFTSE 100 movers: Pharmaceutical stocks lead FTSE's rally
16th Dec 2016 14:11
(ShareCast News) - The FTSE 100 rose 0.11% to 7,006.73 points on Friday afternoon with pharmaceutical stocks leading the way. Hikma Pharmaceuticals, Shire and Astrazeneca rallied on a positive read-across following reports Sanofi is in advanced talks to acquire Actelion. The companies are said to b
Read moreMonday broker round-up
12th Dec 2016 15:55
(ShareCast News) - Greencore: Berenberg reiterates buy with a target price of 350p. Talk Talk: UBS reiterates neutral, 160p target. Barclays: JP Morgan reiterates neutral with a 215p target. Bunzl: Deutsche Bank reiterates buy with a 2450p target. Old Mutual: Barclays downgrades to equal-weight w
Read moreAstraZeneca co-develops treatment for Alzheimer's disease
9th Dec 2016 12:14
(ShareCast News) - Pharmaceutical giant AstraZeneca has teamed up with American counterpart Eli Lilly to co-develop a treatment for Alzheimer's disease (AD). The treatment, called MEDI1814, an antibody selective for amyloid-beta 42,and is currently in Phase 1 trials as a potential disease-modifyi
Read moreWednesday broker round-up
7th Dec 2016 13:36
(ShareCast News) - BHP Billition: HSBC reiterates hold with a target price of 1200p. Bunzl: Goldman Sachs reiterates neutral, 2200p target. Bellway: JP Morgan reiterates overweight with a 2950p target. Aviva: RBC reiterates outperform with a 500p target. IG: Barclays stays at overweight with a 95
Read moreAstraZeneca's Tagrisso cuts lung cancer progression by 70%
6th Dec 2016 09:48
(ShareCast News) - AstraZeneca said on Tuesday that data from a Phase III trial of Tagrisso has shown the medicine is superior to standard chemotherapy for the treatment of lung cancer. The pharmaceuticals giant said the medicine was shown to reduce the risk of lung cancer progression by 70% compare
Read moreAstraZeneca completes sale of US rights for nasal spray
5th Dec 2016 07:05
(ShareCast News) - AstraZeneca has completed the sale of rights to its nasal spray outside of the US with Swiss pharmaceutical Cilag for $330m. The FTSE 100 company sold the rights for Rhinocort Aqua, a nasal spray to treat allergic and nonallergic rhinitis and polyps, for use outside of the US to a
Read morePharma stocks to outperform versus Miners as US dollar gains, Deutsche Bank says
1st Dec 2016 09:42
(ShareCast News) - Pharmaceuticals' recent underperformance versus Mining stocks might be set to end, strategists at Deutsche Bank said. The approximately 5% gain in the US dollar index over the past three months would have been consistent with double-digit outperformance by the former, the investme
Read moreSector movers: Defensives pace gains
25th Nov 2016 16:42
(ShareCast News) - Defensive issues and so-called 'bond proxies' performed best at the tail-end of the week, with shares of personal goods and health care equipment companies pacing gains. Among the former of those two sectors, it was Unilever which did best after the manufacturer said it would appe
Read moreBroker tips: AstraZeneca, Daily Mail, Domino's
25th Nov 2016 15:23
(ShareCast News) - Liberum upgraded AstraZeneca to 'buy' from 'hold'. The brokerage had harboured concerns about the risks to the company's global Phase 3 study of durvalumab, MYSTIC, earnings weakness and bid speculation unwinding. However, with the stock down around 20% and at low not seen since
Read moreLiberum upgrades AstraZeneca to 'buy' from 'hold'
25th Nov 2016 08:37
(ShareCast News) - Liberum upgraded AstraZeneca to 'buy' from 'hold'. The brokerage had harboured concerns about the risks to the company's global Phase 3 study of durvalumab, MYSTIC, earnings weakness and bid speculation unwinding. However, with the stock down around 20% and at lows not seen since
Read moreLondon close: Miners propel FTSE 100 higher as industrial metals surge
22nd Nov 2016 16:34
(ShareCast News) - London equities ended Tuesday on a sharply higher note with major miners storming ahead in tandem with soaring industrial metals prices, and followed by a string of banks and insurers. US interest rate-touch utilities were firmly higher, too. FTSE 100 closed the session up 0.62%
Read moreAstraZeneca resumes enrolment for new cancer drug trial
22nd Nov 2016 07:45
(ShareCast News) - AstraZeneca said on Tuesday that it will resume enrolment for a new cancer drug trial of durvalumab after the US Food and Drug Administration lifted a partial clinical hold on the enrolment of new patients with head and neck cancer. The pharmaceutical company said the Phase III Ke
Read moreThursday broker round-up
17th Nov 2016 13:00
(ShareCast News) - Kingfisher: HSBC reiterates hold with a target price of 380p. Astrazeneca: Berenberg reiterates buy with a 55p target. Aggreko: Jefferies stays at hold with a 750p target. Easyjet: Barclays reiterates equal-weight rating with a 1000p target. Amec Foster Wheeler: UBS keeps at ne
Read moreAstraZeneca completes licensing deal with Allergan
17th Nov 2016 07:20
(ShareCast News) - AstraZeneca announced the completion of the licensing agreement between MedImmune, its global biologics research and development arm, and Allergan, for the global rights to MEDI2070 on Thursday. The FTSE 100 firm said MEDI2070 is an IL-23 monoclonal antibody currently in a Phase I
Read more